1146361-89-8

Basic information

• Product Name: methyl (R)-(4-fluorophenyl)-(2,2,2-trifluoracetylamino)-acetate
• Synonyms: methyl (R)-(4-fluorophenyl)-(2,2,2-trifluoracetylamino)-acetate
• CAS NO: 1146361-89-8
• Molecular Weight: 279.191
• Mol File: 1146361-89-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl (R)-(4-fluorophenyl)-(2,2,2-trifluoracetylamino)-acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (R)-(4-fluorophenyl)-(2,2,2-trifluoracetylamino)-acetate(1146361-89-8)
• EPA Substance Registry System: methyl (R)-(4-fluorophenyl)-(2,2,2-trifluoracetylamino)-acetate(1146361-89-8)

Safety Data

• Hazardous Substances Data: 1146361-89-8(Hazardous Substances Data)

Upstream product

• 407-25-0 trifluoroacetic anhydride 
• 170902-76-8 methyl (R)-amino-(4-fluorophenyl)-acetate 
• 93939-74-3 (R)-2-(4-fluorophenyl)glycine 
• 439213-22-6 methyl (R)-2-amino-2-(4-fluorophenyl)acetate hydrochloride 

Downstream Products

• 1146361-93-4 (R)-1-amino-1-(4-fluorophenyl)-2-methylpropan-2-ol 
• 1146361-95-6 (R)-1-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-ylamino)-1-(4-fluorophenyl)-2-methylpropan-2-ol 
• 1146361-96-7 (R)-1-(2-chloro-5-oxo-6,7-dihydro-5H-5λ⁴-thieno[3,2-d]pyrimidin-4-ylamino)-1-(4-fluorophenyl)-2-methylpropan-2-ol 
• 1146361-91-2 2,2,2-trifluoro-N-[(R)-1-(4-fluorophenyl)-2-hydroxy-2-methylpropyl]-acetamide 

Relevant articles and documents

COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain, in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one EP4 receptor antagonist (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES

The invention relates to new piperidino-dihydrothienopyrimidines of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 may have the meanings given in claim 1, as well as pharmaceutical compositions which contain these compounds. These new piperidino-dihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.